Global Carrier Screening Market - 2022-2029

Global Carrier Screening Market - 2022-2029

Market Overview

The global carrier screening market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Carrier screening is genetic testing used to find faulty genes in fetuses that cause autosomal recessive illnesses. It's a pre-symptomatic and predictive testing tool for pregnant women and couples to assess the likelihood of their child inheriting genetic illnesses from their parents. It entails evaluating a sample of saliva, blood, or cheek tissue for illnesses such cystic fibrosis, sickle cell anemia, and Tay-Sachs disease for the existence of a faulty gene.

Molecular and biological procedures are used to screen these samples based on deoxyribonucleic acid (DNA) sequencing, polymerase chain reaction (PCR), and microarray technologies. They are employed for the expanded, tailored panel, predesigned panel, and focused disease carrier screening for different pulmonary, hematological, and neurological illnesses.

Market Dynamics

The market's expansion is primarily due to a growing focus on early illness detection and prevention and technological breakthroughs in carrier screening. Growing awareness of carrier screening is projected to open up a slew of new potential prospects for industry competitors. Emphasis on early disease detection and prevention will drive the market growth

The major factors driving the carrier screening market forward are the increasing emphasis on early disease detection and prevention, the rising demand for personalized medicine, and the increasing application of screening tests in genetic disorders, which is expected to see a boost during the forecast period. The sooner a disease is detected, the more likely it will be treated or managed successfully. Early treatment of the disease may also make it simpler to live with. Early disease detection allows people to make crucial decisions about their health and support needs and financial and legal matters while they are still able. Inherited diseases like cystic fibrosis, sickle cell anemia, and Tay-Sachs disease are examples of genetic diseases. Carrier testing for such disorders can reveal a couple's chances of having a kid with a genetic disorder. Predictive/presymptomatic testing is the process of identifying risk before symptoms appear. During pregnancy, several genetic abnormalities can be diagnosed early. As a result, customer demand for safe and effective carrier tests is propelling the market forward. In addition, including carrier tests into routine clinical care gives the market a competitive advantage.

According to several studies, early detection of diseases can totally avoid them or at the very least reduce their effects. Several countries' healthcare organisations are financing newborn screening to predict disorders such as malignancies that may develop later in life. During pregnancy, several genetic abnormalities can be diagnosed early. As a result, customer demand for safe and effective carrier tests propels the market forward.

In addition, including carrier tests into routine clinical care gives the market competitive advantage. According to several studies, early detection of diseases can avoid them or at the very least reduce their effects. Several countries' healthcare organizations are financing newborn screening to predict disorders such as malignancies that may develop later in life.

Lack of awareness about new technology is likely to hamper the market growth

The career screening market's growth will be hampered by a lack of awareness of new technology. The lack of fundamental carrier screening requirements will stifle industry growth even further.

COVID-19 Impact Analysis

The Coronavirus disease wreaked havoc on the career screening industry. Various issues, such as financial disruption, supply, and management, resulted in the shutdown of industrial plants for several months. As a result, the market's imbalance between supply and demand widened. Furthermore, following the lifting of the lockdown, several significant competitors began to boost market growth through investments, partnerships, and acquisitions, among other things. In the coming years, the market will experience tremendous expansion.

Segment Analysis

The molecular screening test segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

A molecular screening test detects DNA mutation changes in the genetic code, resulting in reduced enzyme output. It concentrates on mutations seen in a single ethnic group. It entails a step-by-step method of checking for common alleles and thorough gene analysis if necessary. Sequencing is a molecular screening procedure that involves reading across the DNA code of a single gene to see whether there are any known alterations. If the test results are negative, the individual's likelihood of being a carrier is reduced. Still, it does not rule out the possibility of having a carrier gene because the mutation may not have been detected yet using current technology.

Canavan disease, Cystic fibrosis, GM1 gangliosidosis, spinal muscular atrophy, and other significant recessive illnesses benefit from molecular testing. Molecular diagnostics are revolutionizing the practice of medicine by improving prenatal and reproductive care, enabling earlier disease detection, and advancing the treatment of heritable diseases, thanks to advancements in genetic analysis tools such as assays based on next-generation sequencing and microarray technologies. There is a growth in molecular testing because it can improve testing accuracy through technological benefits for many targeted conditions that biochemical testing may not be able to detect.

Geographical Analysis

North America region holds the largest market share of the global carrier screening market

North America is estimated to hold a considerable proportion of the carrier screening market and is predicted to follow a similar pattern during the forecast period, with minor fluctuations. According to the World Health Organization, genetic illness is the primary cause of baby death in the United States, accounting for almost 20% of yearly infant mortality.

Many developments in genomic medicine and technological platforms have enabled obstetric care providers to offer low-cost, panethnic, expanded carrier screening for over 100 recessive genetic disorders. The growing incorporation of genetic medicine into ordinary obstetric practise, however, has generated some worries about carrier testing's practical adoption. According to the Cystic Fibrosis Foundation, more than 30,000 people in the United States have cystic fibrosis, and about 1,000 new instances of cystic fibrosis are diagnosed each year. As the prevalence of genetic illnesses rises year after year, carrier screening is likely to rise as well during the projection period.

Competitive Landscape

The carrier screening market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Quest Diagnostics Incorporated, Sema4, Fulgenmt Genetics Inc, Invitae Corporation, ,Laboratory Corporation of America Holdings, Natera Inc, BGI Group, Bio-Rad Laboratories Inc, Centogene N.V. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the carrier screening market globally. For instance, In January 2020, Quest Diagnostics Inc. has purchased Blueprint Genetics, a company specializing in genetic testing solutions. Through this acquisition, Quest Diagnostics Inc. hopes to obtain experience in rare and genetic disorders, pharmaceutical drug research and development, and patient care practices.

Key Developments

In Feb 2020, Thermo Fisher Scientific Inc. has released a new NGS-based test kit that will allow reproductive health researchers to examine better a wide variety of critical genetic markers using an end-to-end workflow. The Ion Torrent CarrierSeq ECS Kit designed for the Ion GeneStudio S5 System combines a multi-platform expanded carrier screening approach into a single solution, allowing the company to expand its portfolio of reproductive health research services.

Natera Inc

Overview:

Natera, Inc. is a diagnostics firm specializing in the development, commercialization, and discovery of genetic testing services. Panorama non-invasive prenatal test (NIPT), Vistara, Horizon carrier screening (HCS), Spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC), and non-invasive paternity testing are among the services offered by the company (PAT). Constellation is a cloud-based software tool that gives laboratory clients access to algorithms and bioinformatics to validate and conduct experiments based on the technology. Matthew Rabinowitz and Jonathan Sheena launched the company in November 2003, and it is based in Austin, Texas.

Product Portfolio:

Horizon genetic carrier screening: Horizon genetic carrier screening aids parents in determining their child's chance of inheriting major genetic diseases. It can be done either before (ideally) or during (preferably) pregnancy.

Why Purchase the Report?

Visualize the composition of the global carrier screening market segmentation by test type, product & service, disease type, technology, end user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global carrier screening market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global carrier screening market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global carrier screening market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers